` XBIO (Xenetic Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

XBIO
vs
S&P 500

Over the past 12 months, XBIO has underperformed S&P 500, delivering a return of -47% compared to the S&P 500's +14% growth.

Stocks Performance
XBIO vs S&P 500

Loading
XBIO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
XBIO vs S&P 500

Loading
XBIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
XBIO vs S&P 500

Loading
XBIO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Xenetic Biosciences Inc vs Peers

S&P 500
XBIO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Xenetic Biosciences Inc
Glance View

Market Cap
4.9m USD
Industry
Biotechnology

Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.

XBIO Intrinsic Value
3.86 USD
Undervaluation 44%
Intrinsic Value
Price
Back to Top